|
1
|
Nanke Y, Kotake S, Akama H and Kamatani N:
Alkaline phosphatase in rheumatoid arthritis patients: possible
contribution of bone-type ALP to the raised activities of ALP in
rheumatoid arthritis patients. Clin Rheumatol. 21:198–202. 2002.
View Article : Google Scholar
|
|
2
|
Mikuls TR, Saag KG, Criswell LA, et al:
Mortality risk associated with rheumatoid arthritis in a
prospective cohort of older women: results from the Iowa Women’s
Health Study. Ann Rheum Dis. 61:994–999. 2002.PubMed/NCBI
|
|
3
|
Kremer JM, Russell AS, Emery P, et al:
Long-term safety, efficacy and inhibition of radiographic
progression with abatacept treatment in patients with rheumatoid
arthritis and an inadequate response to methotrexate: 3-year
results from the AIM trial. Ann Rheum Dis. 70:1826–1830.
2011.PubMed/NCBI
|
|
4
|
Keystone E, Freundlich B, Schiff M, Li J
and Hooper M: Patients with moderate rheumatoid arthritis (RA)
achieve better disease activity states with etanercept treatment
than patients with severe RA. J Rheumatol. 36:522–531. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baumgartner SW, Fleischmann RM, Moreland
LW, et al: Etanercept (Enbrel) in patients with rheumatoid
arthritis with recent onset versus established disease: improvement
in disability. J Rheumatol. 31:1532–1537. 2004.
|
|
6
|
Wiens A, Correr CJ, Venson R, Otuki MF and
Pontarolo R: A systematic review and meta-analysis of the efficacy
and safety of adalimumab for treating rheumatoid arthritis.
Rheumatol Int. 30:1063–1070. 2010. View Article : Google Scholar
|
|
7
|
Smolen JS, Han C, Bala M, et al ATTRACT
Study Group: Evidence of radiographic benefit of treatment with
infliximab plus methotrexate in rheumatoid arthritis patients who
had no clinical improvement: a detailed subanalysis of data from
the anti-tumor necrosis factor trial in rheumatoid arthritis with
concomitant therapy study. Arthritis Rheum. 52:1020–1030. 2005.
|
|
8
|
Gao GH, Li J, Xie HW and Lü Z: Therapeutic
effect of infliximab on moderate and severe active rheumatoid
arthritis. Nan Fang Yi Ke Da Xue Xue Bao. 30:724–726. 2010.(In
Chinese).
|
|
9
|
Mathias SD, Colwell HH, Miller DP, et al:
Health-related quality of life and functional status of patients
with rheumatoid arthritis randomly assigned to receive etanercept
or placebo. Clin Ther. 22:128–139. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Breedveld FC, Weisman MH, Kavanaugh AF, et
al: The PREMIER study: A multicenter, randomized, double-blind
clinical trial of combination therapy with adalimumab plus
methotrexate versus methotrexate alone or adalimumab alone in
patients with early, aggressive rheumatoid arthritis who had not
had previous methotrexate treatment. Arthritis Rheum. 54:26–37.
2006.
|
|
11
|
Fütterer A, Mink K, Luz A, Kosco-Vilbois
MH and Pfeffer K: The lymphotoxin beta receptor controls
organogenesis and affinity maturation in peripheral lymphoid
tissues. Immunity. 9:59–70. 1998.PubMed/NCBI
|
|
12
|
Visvanathan S, Rahman MU, Keystone E, et
al: Association of serum markers with improvement in clinical
response measures after treatment with golimumab in patients with
active rheumatoid arthritis despite receiving methotrexate: results
from the GO-FORWARD study. Arthritis Res Ther. 12:R2112010.
View Article : Google Scholar
|
|
13
|
Kleinert S, Tony HP, Krause A, et al:
Impact of patient and disease characteristics on therapeutic
success during adalimumab treatment of patients with rheumatoid
arthritis: data from a German noninterventional observational
study. Rheumatol Int. 32:2759–2767. 2012. View Article : Google Scholar
|
|
14
|
Wijbrandts CA, Dijkgraaf MG, Kraan MC, et
al: The clinical response to infliximab in rheumatoid arthritis is
in part dependent on pretreatment tumour necrosis factor alpha
expression in the synovium. Ann Rheum Dis. 67:1139–1144. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feldmann M, Elliott MJ, Woody JN and Maini
RN: Anti-tumor necrosis factor-alpha therapy of rheumatoid
arthritis. Adv Immunol. 64:283–350. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
St. Clair EW, van der Heijde DM, Smolen
JS, et al: Active-controlled study of patients receiving infliximab
for the treatment of rheumatoid arthritis of early onset study
group. Combination of infliximab and methotrexate therapy for early
rheumatoid arthritis: a randomized, controlled trial. Arthritis
Rheum. 50:3432–3443. 2004.
|
|
17
|
Maini RN, Breedveld FC, Kalden JR, et al:
Sustained improvement over two years in physical function,
structural damage, and signs and symptoms among patients with
rheumatoid arthritis treated with infliximab and methotrexate.
Arthritis Rheum. 50:1051–1065. 2004.
|
|
18
|
Takeuchi T, Miyasaka N, Inoue K, Abe T and
Koike T: RISING study: Impact of trough serum level on radiographic
and clinical response to infliximab plus methotrexate in patients
with rheumatoid arthritis: results from the RISING study. Mod
Rheumatol. 19:478–487. 2009. View Article : Google Scholar
|
|
19
|
Delabaye I and De Keyser F; REMITRACT
study group: 74-week follow-up of safety of infliximab in patients
with refractory rheumatoid arthritis. Arthritis Res Ther.
12:R1212010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moreland LW, Baumgartner SW, Schiff MH, et
al: Treatment of rheumatoid arthritis with a recombinant human
tumor necrosis factor receptor(p75)-Fc fusion protein. N Engl J
Med. 337:141–147. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saag KG, Teng GG, Patkar NM, et al:
American College of Rheumatology. American College of Rheumatology
2008 recommendations for the use of nonbiologic and biologic
disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis Rheum. 59:762–784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van der Heijde D, Klareskog L,
Rodriguez-Valverde V, et al: TEMPO Study Investigators. Comparison
of etanercept and methotrexate, alone and combined, in the
treatment of rheumatoid arthritis: two-year clinical and
radiographic results from the TEMPO study, a double-blind,
randomized trial. Arthritis Rheum. 54:1063–1074. 2006.
|
|
23
|
Kavanaugh A, Klareskog L, van der Heijde
D, et al: Improvements in clinical response between 12 and 24 weeks
in patients with-rheumatoid arthritis on etanercept therapy with or
without methotrexate. Ann Rheum Dis. 67:1444–1447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kameda H, Ueki Y, Saito K, et al: Japan
Biological Agent Study Integrated Consortium. Etanercept (ETN) with
methotrexate (MTX) is better than ETN monotherapy in patients with
active rheumatoid arthritis despite MTX therapy: a randomized
trial. Mod Rheumatol. 20:531–538. 2010. View Article : Google Scholar
|
|
25
|
van der Heijde D, Klareskog L, Landewé R,
et al: Disease remission and sustained halting of radiographic
progression with combination etanercept and methotrexate in
patients with rheumatoid arthritis. Arthritis Rheum. 56:3928–3939.
2007.PubMed/NCBI
|
|
26
|
Genovese MC, Bathon JM, Fleischmann RM, et
al: Longterm safety, efficacy, and radiographic outcome with
etanercept treatment in patients with early rheumatoid arthritis. J
Rheumatol. 32:1232–1242. 2005.PubMed/NCBI
|
|
27
|
van der Heijde D, Klareskog L, Singh A, et
al: Patient-reported outcomes in a trial of combination therapy
with etanercept and methotrexate for rheumatoid arthritis: the
TEMPO trial. Ann Rheum Dis. 65:328–334. 2006.
|
|
28
|
Weinblatt ME, Schiff MH, Ruderman EM, et
al: Efficacy and safety of etanercept 50 mg twice a week in
patients with rheumatoid arthritis who had a suboptimal response to
etanercept 50 mg once a week: results of a multicenter, randomized,
double-blind, active drug-controlled study. Arthritis Rheum.
58:1921–1930. 2008. View Article : Google Scholar
|
|
29
|
Johnsen AK, Schiff MH, Mease PJ, et al:
Comparison of 2 doses of etanercept (50 vs 100 mg) in active
rheumatoid arthritis: a randomized double blind study. J Rheumatol.
33:659–664. 2006.PubMed/NCBI
|
|
30
|
van de Putte LB, Atkins C, Malaise M, et
al: Efficacy and safety of adalimumab as monotherapy in patients
with rheumatoid arthritis for whom previous disease-modifying
antirheumatic drug treatment has failed. Ann Rheum Dis. 63:508–516.
2004.PubMed/NCBI
|
|
31
|
Furst DE, Schiff MH, Fleischmann RM, et
al: Adalimumab, a fully human anti tumor necrosis factor-alpha
monoclonal antibody, and concomitant standard antirheumatic therapy
for the treatment of rheumatoid arthritis: results of STAR (Safety
Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol.
30:2563–2571. 2003.
|
|
32
|
Kavanaugh A, Fleischmann RM, Emery P, et
al: Clinical, functional and radiographic consequences of achieving
stable low disease activity and remission with adalimumab plus
methotrexate or methotrexate alone in early rheumatoid arthritis:
26-week results from the randomised, controlled OPTIMA study. Ann
Rheum Dis. May 19–2012.(Epub ahead of print).
|
|
33
|
Keystone EC, Kavanaugh AF, Sharp JT, et
al: Radiographic, clinical, and functional outcomes of treatment
with adalimumab (a human anti-tumor necrosis factor monoclonal
antibody) in patients with active rheumatoid arthritis receiving
concomitant methotrexate therapy: a randomized, placebo-controlled,
52-week trial. Arthritis Rheum. 50:1400–1411. 2004.
|
|
34
|
Keystone EC, Kavanaugh A, Weinblatt ME,
Patra K and Pangan AL: Clinical consequences of delayed addition of
adalimumab to methotrexate therapy over 5 years in patients with
rheumatoid arthritis. J Rheumatol. 38:855–862. 2011.PubMed/NCBI
|
|
35
|
Takeuchi T, Tanaka Y, Kaneko Y, et al:
Effectiveness and safety of adalimumab in Japanese patients with
rheumatoid arthritis: retrospective analyses of data collected
during the first year of adalimumab treatment in routine clinical
practice (HARMONY study). Mod Rheumatol. 22:327–338. 2012.
|
|
36
|
Strand V, Rentz AM, Cifaldi MA, et al:
Health-related quality of life outcomes of adalimumab for patients
with early rheumatoid arthritis: results from a randomized
multicenter study. J Rheumatol. 39:63–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Keystone EC, Genovese MC, Klareskog L, et
al: Golimumab, a human antibody to tumour necrosis factor {alpha}
given by monthly subcutaneous injections, in active rheumatoid
arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann
Rheum Dis. 68:789–796. 2009.
|
|
38
|
Shealy D, Cai A, Staquet K, et al:
Characterization of golimumab, a human monoclonal antibody specific
for human tumor necrosis factor alpha. MAbs. 2:428–439. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kay J, Matteson EL, Dasgupta B, et al:
Golimumab in patients with active rheumatoid arthritis despite
treatment with methotrexate: a randomized, double-blind,
placebo-controlled, dose-ranging study. Arthritis Rheum.
58:964–975. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weinblatt ME, Bingham CO III, Mendelsohn
AM, et al: Intravenous golimumab is effective in patients with
active rheumatoid arthritis despite methotrexate therapy with
responses as early as week 2: results of the phase 3, randomised,
multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann
Rheum Dis. Jun 1–2012.(Epub ahead of print).
|
|
41
|
Genovese MC, Han C, Keystone EC, et al:
Effect of golimumab on patient-reported outcomes in rheumatoid
arthritis: Results from the GO-FORWARD Study. J Rheumatol.
39:1185–1191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tanaka Y, Harigai M, Takeuchi T, et al the
GO-FORTH Study Group: Golimumab in combination with methotrexate in
Japanese patients with active rheumatoid arthritis: results of the
GO-FORTH study. Ann Rheum Dis. 71:817–824. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Emery P, Fleischmann RM, Moreland LW, et
al: Golimumab, a human anti-tumor necrosis factor alpha monoclonal
antibody, injected subcutaneously every four weeks in
methotrexate-naive patients with active rheumatoid arthritis:
twenty-four-week results of a phase III, multicenter, randomized,
double-blind, placebo-controlled study of golimumab before
methotrexate as first-line therapy for early-onset rheumatoid
arthritis. Arthritis Rheum. 60:2272–2283. 2009.
|
|
44
|
Nesbitt A, Fossati G, Bergin M, et al:
Mechanism of action of certolizumab pegol (CDP870): in vitro
comparison with other anti-tumor necrosis factor alpha agents.
Inflamm Bowel Dis. 13:1323–1332. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Smolen J, Landewe RB, Mease P, et al:
Efficacy and safety of certolizumab pegol plus methotrexate in
active rheumatoid arthritis: the RAPID 2 study. A randomised
controlled trial. Ann Rheum Dis. 68:797–804. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Keystone E, Heijde D, Mason D Jr, et al:
Certolizumab pegol plus methotrexate is significantly more
effective than placebo plus methotrexate in active rheumatoid
arthritis: findings of a fifty-two-week, phase III, multicenter,
randomized, double-blind, placebo-controlled, parallel-group study.
Arthritis Rheum. 58:3319–3329. 2008. View Article : Google Scholar
|
|
47
|
Fleischmann R, Vencovsky J, van
Vollenhoven RF, et al: Efficacy and safety of certolizumab pegol
monotherapy every 4 weeks in patients with rheumatoid arthritis
failing previous disease-modifying antirheumatic therapy: the
FAST4WARD study. Ann Rheum Dis. 68:805–811. 2009. View Article : Google Scholar
|
|
48
|
Keystone EC, Combe B, Smolen J, et al:
Sustained efficacy of certolizumab pegol added to methotrexate in
the treatment of rheumatoid arthritis: 2-year results from the
RAPID 1 trial. Rheumatology (Oxford). 51:1628–1638. 2012.PubMed/NCBI
|
|
49
|
Curtis JR, Chen L, Luijtens K, et al: Dose
escalation of certolizumab pegol from 200 mg to 400 mg every other
week provides no additional efficacy in rheumatoid arthritis: an
analysis of individual patient-level data. Arthritis Rheum.
63:2203–2208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kekow J, Moots RJ, Emery P, et al:
Patient-reported outcomes improve with etanercept plus methotrexate
in active early rheumatoid arthritis and the improvement is
strongly associated with remission: The COMET trial. Ann Rheum Dis.
69:222–225. 2010. View Article : Google Scholar
|
|
51
|
Weinblatt ME, Kremer JM, Bankhurst AD, et
al: A trial of etanercept, a recombinant tumor necrosis factor
receptor: Fc fusion protein, in patients with rheumatoid arthritis
receiving methotrexate. N Engl J Med. 340:253–259. 1999. View Article : Google Scholar
|
|
52
|
Haraoui B, Cividino A, Stewart J, Guérette
B and Keystone EC: Safety and effectiveness of adalimumab in a
clinical setting that reflects Canadian standard of care for the
treatment of rheumatoid arthritis (RA): results from the CanACT
study. BMC Musculoskelet Disord. 12:261–270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Aaltonen KJ, Virkki LM, Malmivaara A, et
al: Systematic review and meta-analysis of the efficacy and safety
of existing TNF blocking agents in treatment of rheumatoid
arthritis. PLoS One. 7:e30275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Caporali R, Pallavicini FB, Filippini M,
et al: Treatment of rheumatoid arthritis with anti-TNF-alpha
agents: a reappraisal. Autoimmun Rev. 8:274–280. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hyrich KL, Lunt M, Watson KD, Symmons DP
and Silman AJ; British Society for Rheumatology Biologics Register:
Outcomes after switching from one anti-tumor necrosis factor alpha
agent to a second anti-tumor necrosis factor alpha agent in
patients with rheumatoid arthritis: results from a large UK
national cohort study. Arthritis Rheum. 56:13–20. 2007. View Article : Google Scholar
|
|
56
|
Hetland ML, Christensen IJ, Tarp U, et al:
Direct comparison of treatment responses, remission rates, and drug
adherence in patients with rheumatoid arthritis treated with
adalimumab, etanercept, or infliximab: results from eight years of
surveillance of clinical practice in the nationwide Danish DANBIO
registry. Arthritis Rheum. 62:22–32. 2010.
|
|
57
|
Singh JA, Christensen R, Wells GA, et al:
Biologics for rheumatoid arthritis: an overview of Cochrane
reviews. Sao Paulo Med J. 128:309–310. 2010.PubMed/NCBI
|
|
58
|
Fonseca JE, Canhão H, Silva C, et al:
Grupo de Estudos de Artrite Reumatóide da Sociedade Portuguesa de
Reumatologia. Tuberculosis in rheumatic patients treated with
tumour necrosis factor alpha antagonists: the Portuguese
experience. Acta Reumatol Port. 31:247–253. 2006.(In
Portuguese).
|
|
59
|
Nam JL, Winthrop KL, van Vollenhoven RF,
et al: Current evidence for the management of rheumatoid arthritis
with biological disease-modifying antirheumatic drugs: a systematic
literature review informing the EULAR recommendations for the
management of RA. Ann Rheum Dis. 69:976–986. 2010. View Article : Google Scholar
|
|
60
|
Curtis JR, Xie F, Chen L, et al: The
comparative risk of serious infections among rheumatoid arthritis
patients starting or switching biological agents. Ann Rheum Dis.
70:1401–1406. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Singh JA, Wells GA, Christensen R, et al:
Adverse effects of biologics: a network meta-analysis and Cochrane
overview. Cochrane Database Syst Rev. 16:CD0087942011.PubMed/NCBI
|
|
62
|
Hansen KE, Hildebrand JP, Genovese MC, et
al: The efficacy of switching from etanercept to infliximab in
patients with rheumatoid arthritis. J Rheumatol. 31:1098–1102.
2004.PubMed/NCBI
|
|
63
|
Furst DE, Gaylis N, Bray V, et al:
Open-label, pilot protocol of patients with rheumatoid arthritis
who switch to infliximab after an incomplete response to
etanercept: the opposite study. Ann Rheum Dis. 66:893–899. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wick MC, Ernestam S, Lindblad S, et al:
Adalimumab (Humira) restores clinical response in patients with
secondary loss of efficacy from infliximab (Remicade) or etanercept
(Enbrel): results from the STURE registry at Karolinska University
Hospital. Scand J Rheumatol. 34:353–358. 2005. View Article : Google Scholar
|
|
65
|
Hyrich KL, Lunt M, Dixon WG, Watson KD and
Symmons DP; BSR Biologics Register: Effects of switching between
anti-TNF therapies on HAQ response in patients who do not respond
to their first anti-TNF drug. Rheumatology (Oxford). 47:1000–1005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Scrivo R, Conti F, Spinelli FR, et al:
Switching between TNFalpha antagonists in rheumatoid arthritis:
personal experience and review of the literature. Reumatismo.
61:107–117. 2009.PubMed/NCBI
|
